Differential Osteoprotegerin Kinetics after Stimulation with Desmopressin and Lipopolysaccharides In Vivo.


Journal

Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063

Informations de publication

Date de publication:
Jul 2020
Historique:
pubmed: 3 6 2020
medline: 3 6 2021
entrez: 3 6 2020
Statut: ppublish

Résumé

Osteoprotegerin (OPG) regulates bone metabolism by reducing the activation of osteoclasts, but may also be involved in blood vessel calcification and atherosclerosis. Within endothelial cells OPG is stored in Weibel-Palade bodies (WPBs). Blood kinetics of OPG are essentially unknown. We aimed to assess these using two distinct in vivo models; one after stimulation with desmopressin (DDAVP) and another after stimulation with lipopolysaccharide (LPS). Both clinical trials were conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, Austria. Participants received desmopressin (0.3 µg/kg), LPS (2 ng/kg), or placebo (sodium chloride 0.9%) with subsequent blood sampling at time points up to 24 hours after administration. The primary objective of this study was to investigate the plasma kinetics of OPG after stimulation with desmopressin and LPS. Secondary analyses included the release of other WPB contents including von Willebrand factor (vWF). This analysis included 31 healthy volunteers (

Identifiants

pubmed: 32483770
doi: 10.1055/s-0040-1712448
doi:

Substances chimiques

Biomarkers 0
Lipopolysaccharides 0
Osteoprotegerin 0
TNFRSF11B protein, human 0
von Willebrand Factor 0
Deamino Arginine Vasopressin ENR1LLB0FP

Types de publication

Comparative Study Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1108-1115

Subventions

Organisme : SFB54-04/APF05404FW
ID : Austrian Science Fund FWF

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Nina Buchtele (N)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Katarina D Kovacevic (KD)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Christine Brostjan (C)

Department of Surgery, Medical University of Vienna, Vienna, Austria.

Michael Schwameis (M)

Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.

Hubert Hayden (H)

Department of Surgery, Medical University of Vienna, Vienna, Austria.

Ulla Derhaschnig (U)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Christa Firbas (C)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Bernd Jilma (B)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Christian Schoergenhofer (C)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH